TORONTO, ON--(Marketwired - Jul 29, 2015) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces the appointment of Evan Karras as CEO & Director and announces Mr. Nunzio Valerie as President and Director.
Easton Pharmaceuticals is pleased to announce the appointment of highly successful businessman, Evan Karras as CEO & Director, replacing Carla Pepe, who will assume the role of Secretary and Director. Easton is also pleased to announce the appointment of Mr. Nunzio Valerie, who previously worked as a well respected broker for 14 years as well as holding positions with several venture capital firms. Mr. Valerie will remain as President and has also assumed the position of CFO. Mr. Karras brings a wealth of knowledge and experience in the implementation of small, medium and large-scale projects on both national and international levels to Easton. A few of Mr. Karras's significant accomplishments include:
- The launch of the first Direct Marketing Company in the Middle East for a personal care products company he founded.
- Ranked 35th by Price Waterhouse Cooper among the most respected businessmen during his tenure as President & CEO of Telemax, the largest supplier of prepaid calling products in Canada.
- Masters' degree in Business & Finance.
- Other highly successful commercial ventures totalling hundreds of millions of dollars.
Mr. Karras stated, "Timing is everything, and I see this opportunity with Easton Pharmaceuticals as an extremely high-growth undertaking. What especially excites me is that Easton is in a ground-floor position to leverage its partnerships in the Women's Health arena and make a major impact in the market with the launch of a suite of patented, in-licensed products in Latin America, a unique position when one considers these same licenses were negotiated for in other territories by some of the largest pharma companies in the world." Mr. Karras further commented, "Latin America is a very high-growth region for the pharmaceutical industry and I can see additional opportunities for Easton revenues in generic cancer drug sales, as well as with the development of its proprietary cancer compounds. We intend to not only grow in Latin America but across the world in other markets such as the Middle East, and even North America, with some of the other unique product offerings Easton has within the Women's Health industry."
The appointment of Mr. Karras is a precursor to other very notable corporate appointments and other positive business related developments and closed agreements to be shortly announced.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women's diagnostic products and two generic cancer products. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; a company holding Medical Marijuana growing rights in California on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and hold an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.